GSK submits non-statistically significant NDA for Promacta
Pharmababble's author writes:
An FDA reviewer said that Promacta, an experimental platelet-boosting drug seeking an indication for acute treatment of chronic idiopathic thrombocytopenia purpura from GSK, did not help control bleeding any better than a placebo. The reviewer wrote:
“The data provided in this NDA (new drug application) do not demonstrate statistically significant, robust … treatment effect in decreasing bleeding events,”
The FDA is already being stingy about approving NDAs when they demonstrate statistically significant effects. I can’t imagine the advisory board, which meets Friday, is going to issue a positive opinion about recommending an acute therapy for a chronic disease state, especially with non-statistically significant results.
I’m not a regulatory guy, so anyone want to explain the GSK reasoning to me?
Read the new book, The Evidence, However, Is Clear...The Seroxat Scandal
By Bob Fiddaman
AVAILABLE FOR DOWNLOAD HERE
PAPERBACK COMING SOON